Reduction in the Incidence of Diabetes

The observations that fewer patients randomized to captopril developed diabetes than those randomized to the P-blocker in the CAPPP trial was initially met with skepticism about whether it was a real reduction with the ACE inhibitor or an increase in incidence of diabetes produced by the P-blocker comparator.6

However, this objection cannot apply to the results of the HOPE trial, which showed a 30% reduction in the new incidence of diabetes in the ramipril arm.98 There has been a rather consistent reduction in diabetes as assessed as a secondary end point in some of the major trials, including ALLHAT10 and PEACE.100

Similarly, major studies in hypertension comparing ARBs with other antihypertensive agents, such as in

LIFE13 and VALUE,15 and with placebo, such as in the

CHARM heart failure program,43 have indicated that both pharmacologic inhibitors of the RAS reduced the risk of developing new-onset diabetes. A meta-

analysis showed an approximately 20% reduction in the risk of developing diabetes in subjects receiving an ACE inhibitor or ARB.131

These observations have spurred basic research that has uncovered multiple potential mechanisms, such as reducing potential angiotensin II effect on the pancreatic fibrosis, improving insulin sensitivity in skeletal muscle, improving insulin signaling pathways, and other mechanisms whereby RAS

inhibition could influence glucose homeostasis.132 However, all the consistent and important observations from clinical trials must be considered as nondefinitive because they were derived from secondary end points from studies that were designed to address other questions. As part of a two-by-two factorial design, the Diabetes Reduction Assessment with Ramipril and Rosiglitazone (DREAM) study much more directly and rigorously tested whether an ACE inhibitor could reduce the development of diabetes in an at-risk population.133 Although the primary end point of incidence of diabetes or death was 9% lower in the ACE inhibitor group, this difference was not statistically significant. A strong suggestion of an effect on glucose metabolism was, however, observed on prespecified secondary outcomes. An accompanying editorial indicated that hospitaliza-tion and ascertainment bias could have overestimated the RAS inhibitor influence on the incidence of diabetes in the prior trials and that the 95% confidence interval of DREAM (0.81 to 1.05) still encompassed an important possible benefit.134 The ongoing Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR), with more than 9000 subjects with impaired glucose tolerance randomized as part of a two-by-two factorial to the ARB valsartan or placebo, should settle this important issue.135

Renin Inhibitor Challenge

The cascade that leads to angiotensin II commences with the enzyme renin, which cleaves the peptide angiotensin I from angiotensinogen (see Fig. 12-1). Until recently, this first reaction has not been a clinically available pharmacologic target for inhibiting the RAS.136,137 Theoretically, inhibition at this site of initiation may provide a unique way to reduce both angiotensin I and II levels while preventing exposure to compensatory escape mechanisms. Renin inhibition would also be anticipated to reduce the influence of other angiotensin peptides138 more than ACE inhibitors or ARBs. Alternatively, combining a renin inhibitor with an inhibitor of angiotensin II generation (ACE inhibitor) or end receptor blocker (ARB) may provide the most effective means for long-term RAS inhibition. Commercialization of oral renin inhibitors has been severely hampered by a combination of poor bioavailability and a relatively expensive generation and production process. One agent, aliskiren, is emerging as an effective and apparently well-tolerated antihypertensive therapy.137 The relative merits and clinical usage will undoubtedly depend on clinical outcome studies that go beyond the surrogate of blood pressure reduction. For this agent to be a commercial success, the medical community must be convinced by robust outcomes studies, such as have been conducted with the ACE inhibitors and ARBs, that a renin inhibitor alone or in combination with other proven pharmacologic therapies is safe and effective in reducing cardiovascular risk to justify usage of a new agent.

CONCLUSIONS

The clinical utility of ACE inhibitors has evolved from limited use in severe, refractory hypertension to first-line therapy for essential hypertension. A similar pattern has emerged in the management of patients with ventricular dysfunction. ACE inhibitors were initially administered only to severely compromised patients with heart failure, until further studies (e.g., SOLVD, Pre-SAVE) demonstrated the survival benefits of ACE inhibitors in milder degrees of congestive heart failure and even when used in a preventive manner before the clinical manifestation of overt heart failure in patients with asymptomatic left ventricular dysfunction. With the proven benefits of ACE inhibitors first observed during acute and chronic MI, studies have now extended proof of benefits to high-risk vascular disease and stroke patients. This pattern of testing from severe to milder forms of disease was also used for patients with vascular disease. The development of ARBs offers a unique opportunity to determine whether more complete inhibition of the RAS could produce additional clinical benefits. This is an active area of clinical investigation that will likely determine the relative roles of ACE inhibitors and ARBs alone or in combination. The expanding indications for ACE inhibitor and ARB use have been based on an exciting convergence of basic and clinical investigations that have improved our understanding of pathophysiology, vascular biology, and patient care.

Some of the advancements in the use of these inhibitors of the RAS stemmed from hypotheses derived from basic laboratory research, such as renal nephron protection and the attenuation of adverse left ventricular remodeling after MI, which were translated into clinical benefits by randomized, controlled clinical trials. Other leads for innovative areas of research stemmed from observations of secondary, often not prespecified, end points from the clinical trial experience. These initially unexpected findings, such as reductions in atherosclerotic events and reductions of the incidence of diabetes and atrial fibrillation,139 provided the impetus for new randomized trials and important mechanistic studies. Inhibiting the angiotensin axis is perhaps one of the best examples of the importance of cross-fertilization between clinical outcomes and basic mechanistic studies.

REFERENCES

1. Pfeffer MA, Frohlich ED: Improvements in clinical outcomes with the use of angiotensin-converting enzyme inhibitors: Cross-fertilization between clinical and basic investigation. Am J Physiol 2006;291:H2021-H2025.

2. Lloyd-Jones DM, Evans JC, Levy D: Hypertension in adults across the age spectrum: Current outcomes and control in the community. JAMA 2005;294:466-472.

3. Turnbull F: Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of pro-spectively-designed overviews of randomised trials. Lancet 2003;362:1527-1535.

4. Williams B: Recent hypertension trials: Implications and controversies. J Am Coll Cardiol 2005;45:813-827.

5. Leenen FH, Nwachuku CE, Black HR, et al: Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension 2006; 48: 374-384.

6. Hansson L, Lindholm LH, Niskanen L, et al: Effect of angio-tensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999;353:611-616.

7. UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and micro-vascular complications in type 2 diabetes: UKPDS 39. BMJ 1998;317:713-720.

8. Davis BR, Cutler JA, Gordon DJ, et al: Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group. Am J Hypertens 1996;9:342-360.

9. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlortha-lidone: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000;283: 1967-1975.

10. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-2997.

11. Wing LM, Reid CM, Ryan P, et al: A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003;348: 583-592.

12. Okin PM, Devereux RB, Jern S, et al: Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: The Losartan intervention for endpoint reduction (LIFE) in hypertension study. The Life Study Investigators. Hypertension 2000;36:766-773.

13. Dahlöf B, Devereux RB, Kjeldsen SE, et al: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002;359:995-1003.

14. Lithell H, Hansson L, Skoog I, et al: The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875-886.

15. Kjeldsen SE, Julius S, Brunner H, et al: Characteristics of 15,314 hypertensive patients at high coronary risk. The VALUE trial. The Valsartan Antihypertensive Long-term Use Evaluation. Blood Press 2001;10:83-91.

16. Schrader J, Luders S, Kulschewski A, et al: Morbidity and mortality after stroke, eprosartan compared with nitrendip-ine for secondary prevention: Principal results of a prospective randomized controlled study (MOSES). Stroke 2005;36:1218-1226.

17. Dahlöf B, Sever PS, Poulter NR, et al: Prevention of cardiovascular events with an antihypertensive regimen of amlo-dipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet 2005;366:895-906.

18. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-1462.

19. Agodoa LY, Appel L, Bakris GL, et al: Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclero-sis: A randomized controlled trial. JAMA 2001; 285: 2719-2728.

20. Ruggenenti P, Fassi A, Ilieva AP, et al: Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941-1951.

21. Brenner BM, Cooper ME, de Zeeuw D, et al: Effects of losarían on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869.

22. Lewis EJ, Hunsicker LG, Clarke WR, et al: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860.

23. Berl T, Hunsicker LG, Lewis JB, et al: Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 2003;138:542-549.

24. Parving HH, Lehnert H, Brochner-Mortensen J, et al: The effect of irbesartan on the development of diabetic nephrop-athy in patients with type 2 diabetes. N Engl J Med 2001;345: 870-878.

25. Viberti G, Wheeldon NM: Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: A blood pressure-independent effect. Circulation 2002;106:672-678.

26. Hostetter TH: Prevention of end-stage renal disease due to type 2 diabetes. N Engl J Med 2001;345:910-912.

27. Casas JP, Chua W, Loukogeorgakis S, et al: Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: Systematic review and metaanalysis. Lancet 2005; 366:2026-2033.

28. Remuzzi G, Ruggenenti P: Overview of randomised trials of ACE inhibitors. Lancet 2006;368:555-556.

29. Levey AS, Coresh J, Balk E, et al: National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med 2003;139: 137-147.

30. Nakao N, Yoshimura A, Morita H, et al: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial. Lancet 2003; 361:117-124.

31. MacKinnon M, Shurraw S, Akbari A, et al: Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: A systematic review of the efficacy and safety data. Am J Kidney Dis 2006;48:8-20.

32. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enala-pril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987;316:1429-1435.

33. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991;325:293-302.

34. Cohn JN, Johnson G, Ziesche S, et al: A comparison of enala-pril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325: 303-310.

35. Hunt SA, Baker DW, Chin MH, et al: ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2001;38:2101-2113.

36. Swedberg K, Cleland J, Dargie H, et al: Guidelines for the diagnosis and treatment of chronic heart failure: Executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:1115-1140.

37. Adams JF, Lindenfeld J, Arnold JMO, et al: HFSA 2006 Comprehensive Heart Failure Practice Guideline. Journal of Cardiac Failure 2006;12:e1-e122.

38. Skali H, Pfeffer MA: Prospects for ARB in the next five years. J Renin Angiotensin Aldosterone Syst 2001;2:215-218.'

39. Pitt B, Segal R, Martinez FA, et al: Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349:747-752.

40. Pitt B, Poole-Wilson PA, Segal R, et al: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial—the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-1587.

41. Cohn JN, Tognoni G: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-1675.

42. Anand IS, Wong M, Latini R, et al: Relation between changes in ejection fraction over time and subsequent mortality and morbidity in Val-HeFT [abstract]. J Am Coll Cardiol 2003;41(Suppl A):212A

43. Pfeffer MA, Swedberg K, Granger CB, et al: Effects of cande-sartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme. Lancet 2003;362:759-766.

44. Granger CB, McMurray JJ, Yusuf S, et al: Effects of candesar-tan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: The CHARM-Alternative trial. Lancet 2003;362:772-776.

45. McMurray JJ, Östergren J, Swedberg K, et al: Effects of cande-sartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-convert-ing-enzyme inhibitors: The CHARM-Added trial. Lancet 2003;362:767-771.

46. McMurray JJ, Young JB, Dunlap ME, et al: Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. Am Heart J 2006;151:985-991.

47. http://www.fda.gov/cder/foi/appletter/2005/020838s022ltr. pdf

48. Yusuf S, Pfeffer MA, Swedberg K, et al: Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial. Lancet 2003;362:777-781.

49. Owan TE, Hodge DO, Herges RM, et al: Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006;355:251-259.

50. Bhatia RS, Tu JV, Lee DS, et al: Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006;355:260-269.

51. Cleland JG, Tendera M, Adamus J, et al: The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006;27:2338-2345.

52. Carson P, Massie BM, McKelvie R, et al: The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: Rationale and design. J Card Fail 2005;11:576-585.

53. Pfeffer JM, Pfeffer MA, Fletcher PJ, Braunwald E: Progressive ventricular remodeling in rat with myocardial infarction. Am J Physiol 1991;260:H1406-H1414.

54. Pfeffer JM, Pfeffer MA, Braunwald E: Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res 1985;57:84-95.

55. Pfeffer MA, Braunwald E: Ventricular remodeling after myo-cardial infarction. Experimental observations and clinical implications. Circulation 1990;81:1161-1172.

56. Hammermeister KE, DeRouen TA, Dodge HT: Variables predictive of survival in patients with coronary disease: Selection by univariate and multivariate analyses from the clinical, electrocardiographic, exercise, arteriographic, and quantitative angiographic evaluations. Circulation 1979;59: 421-430.

57. White HD, Norris RM, Brown MA, et al: Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987;76: 44-51.

58. Pfeffer MA, Pfeffer JM, Steinberg C, Finn P: Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. Circulation 1985;72: 406-412.

59. Pfeffer MA, Lamas GA, Vaughan DE, et al: Effect of captopril on progressive ventricular dilatation after anterior myocar-dial infarction. N Engl J Med 1988;319:80-86.

60. Sharpe N, Smith H, Murphy J, Hannan S: Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction. Lancet 1988;1:255-259.

61. Latini R, Maggioni AP, Flather M, et al: ACE inhibitor use in patients with myocardial infarction. Summary of evidence from clinical trials. Circulation 1995;92:3132-3137.

62. Flather MD, Yusuf S, K0ber L, et al: Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000;355:1575-1581.

63. Pfeffer MA, Braunwald E, Moye LA, et al: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival And Ventricular Enlargement trial. N Engl J Med 1992; 327:669-677.

64. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-828.

65. K0ber L, Torp-Pedersen C, Carlsen JE, et al: A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995;333:1670-1676.

66. Ambrosioni E, Borghi C, Magnani B: The effect of the angio-tensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med 1995;332:80-85.

67. Swedberg K, Held P, Kjekshus J, et al: Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992;327:678-684.

68. Furberg CD, Campbell RW, Pitt B: ACE inhibitors after myocardial infarction [letter]. N Engl J Med 1993;328:967-968.

69. Gruppo Italiano per lo Studio della Sopravvivenza Nell'Infarto Miocardico (GISSI)-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-1122.

70. Fourth International Study of Infarct Survival (ISIS-4): A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995;345:669-685.

71. Chinese Cardiac Study Collaborative Group: Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: Interim report from the Chinese Cardiac Study (CC-1). Lancet 1995;345:686-687.

72. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: Systematic overview of individual data from 100,000 patients in randomized trials. Circulation 1998;97:2202-2212.

73. Pfeffer MA: ACE inhibition in acute myocardial infarction [editorial]. N Engl J Med 1995;332:118-120.

74. Pfeffer MA, Greaves SC, Arnold JM, et al: Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The Healing and Early Afterload Reducing Therapy trial. Circulation 1997;95:2643-2651.

75. Antman EM, Anbe DT, Armstrong PW, et al: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction—Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004; 110: 588-636.

76. Hall D: The aspirin-angiotensin-converting enzyme inhibitor tradeoff: To halve and halve not. J Am Coll Cardiol 2000;35:1808-1812.

77. Pfeffer MA: Clinical accomplishments of ACE inhibition therapy: With and without aspirin. In: Goldhaber SZ, Ridker PM, eds. Thrombosis and Thromboembolism. New York: Marcel Dekker, 2002, pp 145-159.

78. Dickstein K, Kjekshus J: Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: The OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002;360:752-760.

79. Tokmakova M, Solomon SD: Inhibiting the renin-angioten-sin system in myocardial infarction and heart failure: Lessons from SAVE, VALIANT and CHARM, and other clinical trials. Curr Opin Cardiol 2006;21:268-272.

80. Pfeffer MA, McMurray JJ, Velazquez EJ, et al: Valsartan, cap-topril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-906.

81. http://www.fda.gov/medwatch/safety/2005/aug_PI/Diovan_PI.pdf

82. http://www.jointcommission.org/NR/rdonlyres/A73B9038-87B2-4F92-81EF-9DE408EFB90B/0/ChangeinACEIforLVSD-MeasuresIncorpARBs.pdf

83. Mann DL, Deswal A: Angiotensin-receptor blockade in acute myocardial infarction—A matter of dose. N Engl J Med 2003;349:1963-1965.

84. McMurray JJ, Pfeffer MA, Swedberg K, Dzau VJ: Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction? Circulation 2004;110:3281-3288.

85. Struthers AD: Aldosterone blockade in cardiovascular disease. Heart 2004;90:1229-1234.

86. Cohn JN, Colucci W: Cardiovascular effects of aldosterone and post-acute myocardial infarction pathophysiology. Am J Cardiol 2006;97:4F-12F.

87. Pitt B, Zannad F, Remme WJ, et al: The effect of spironolac-tone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-717.

88. Pitt B, Williams G, Remme W, et al: The EPHESUS trial: Eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 2001;15:79-87.

89. McMurray JJ, Pfeffer MA: Heart failure. Lancet 2005;365: 1877-1889.

90. Mielniczuk L, Stevenson LW: Angiotensin-converting enzyme inhibitors and angiotensin II type I receptor blockers in the management of congestive heart failure patients: What have we learned from recent clinical trials? Curr Opin Cardiol 2005;20:250-255.

91. Juurlink DN, Mamdani MM, Lee DS, et al: Rates of hyperka-lemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004;351:543-551.

92. McMurray JJ, O'Meara E: Treatment of heart failure with spironolactone—trial and tribulations. N Engl J Med 2004;351:526-528.

93. Desai AS, McMurray JJV, Granger CB, et al: Incidence and predictors of hyperkalemia in patients with heart failure—an analysis of the Candesartan in Heart failure—Assessment of Reduction in Mortality and morbidity (CHARM) program [abstract 531]. Eur J Heart Fail Suppl 2006;5:115.

94. Rutherford JD, Pfeffer MA, Moyé LA, et al: Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. Circulation 1994;90:1731-1738.

95. Yusuf S, Pepine CJ, Garces C, et al: Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992;340:1173-1178.

96. Alderman MH, Madhavan S, Ooi WL, et al: Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991;324: 1098-1104.

97. Danchin N, Cucherat M, Thuillez C, et al: Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: An overview of long-term randomized controlled trials. Arch Intern Med 2006;166:787-796.

98. Yusuf S, Sleight P, Pogue J, et al: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342: 145-153.

99. Fox KM, Henderson JR, Bertrand ME, et al: The European trial on reduction of cardiac events with perindopril in stable coronary artery disease (EUROPA). Eur Heart J 1998;19(Suppl J):J52-J55.

100. Braunwald E, Domanski MJ, Fowler SE, et al: Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351:2058-2068.

101. Pitt B: ACE inhibitors for patients with vascular disease without left ventricular dysfunction—May they rest in PEACE? N Engl J Med 2004;351:2115-2117.

102. Solomon SD, Rice MM, Jablonski KA, et al: Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation 2006;114:26-31.

103. Al-Mallah MH, Tleyjeh IM, Abdel-Latif AA, Weaver WD: Angiotensin-converting enzyme inhibitors in coronary artery disease and preserved left ventricular systolic function: A systematic review and meta-analysis of randomized controlled trials. J Am Coll Cardiol 2006;47:1576-1583.

104. Dagenais GR, Pogue J, Fox K, et al: Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: A combined analysis of three trials. Lancet 2006;368:581-588.

105. Progress Collaborative Group: Randomised trial of a perindo-pril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-1041.

106. The MERCATOR Study Group: Does the new angiotensin converting enyzme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR Study: A multicenter, randomized, double-blind placebo-controlled trial. Circulation 1992;86: 100-110.

107. Faxon DP: Effect of high dose angiotensin-converting enzyme inhibition on restenosis: Final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group. J Am Coll Cardiol 1995;25:362-369.

108. Nissen SE, Tuzcu EM, Libby P, et al: Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: The CAMELOT study: A randomized controlled trial. JAMA 2004;292:2217-2225.

109. Strawn WB, Ferrario CM: Mechanisms linking angiotensin II and atherogenesis. Curr Opin Lipidol 2002;13:505-512.

110. Pagliaro P, Penna C: Rethinking the renin-angiotensin system and its role in cardiovascular regulation. Cardiovasc Drugs Ther 2005;19:77-87.

111. Teo KK, Burton JR, Buller CE, et al: Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/ Enalapril Coronary Atherosclerosis Trial (SCAT). Circulation 2000;102:1748-1754.

112. Weiss D, Kools JJ, Taylor WR: Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice. Circulation 2001;103:448-454.

113. Kon V, Jabs K: Angiotensin in atherosclerosis. Curr Opin Nephrol Hypertens 2004;13:291-297.

114. Ridker PM, Gaboury CL, Conlin PR, et al: Stimulation of plasminogen activator inhibitor in vivo by infusion of angio-tensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation 1993;87:1969-1973.

115. Vaughan DE, Rouleau JL, Ridker PM, et al: Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. Circulation 1997;96:442-447.

116. Mancini GB, Henry GC, Macaya C, et al: Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996;94:258-265.

117. Munzel T, Keaney JF Jr: Are ACE inhibitors a "magic bullet" against oxidative stress? Circulation 2001; 104: 1571-1574.

118. Strawn WB, Chappell MC, Dean RH, et al: Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation 2000;101:1586-1593.

119. Chen J, Mehta JL: Angiotensin II-mediated oxidative stress and procollagen-1 expression in cardiac fibroblasts: blockade by pravastatin and pioglitazone. Am J Physiol 2006;291: H1738-H1745.

120. Limor R, Kaplan M, Sawamura T, et al: Angiotensin II increases the expression of lectin-like oxidized low-density lipoprotein receptor-1 in human vascular smooth muscle cells via a lipoxygenase-dependent pathway. Am J Hypertens 2005;18:299-307.

121. Graninger M, Reiter R, Drucker C, et al: Angiotensin receptor blockade decreases markers of vascular inflammation. J Cardiovasc Pharmacol 2004;44:335-339.

122. Browatzki M, Larsen D, Pfeiffer CA, et al: Angiotensin II stimulates matrix metalloproteinase secretion in human vascular smooth muscle cells via nuclear factor-kappaB and activator protein 1 in a redox-sensitive manner. J Vasc Res 2005;42:415-423.

123. Di Napoli M, Papa F: Angiotensin-converting enzyme inhibitor use is associated with reduced plasma concentration of C-reactive protein in patients with first-ever ischemic stroke. Stroke 2003;34:2922-2929.

124. Sabatine MS, Morrow DA, Jablonski KA, et al: Investigation of the relation between the new AHA/CDC C-reactive protein cutpoints and cardiovascular outcomes and incident diabetes in patients with stable coronary disease: A PEACE substudy. J Am Coll Cardiol 2006;47(Suppl A):222A.

125. Strauss MH, Hall AS: Angiotensin receptor blockers may increase risk of myocardial infarction: Unraveling the ARB-MI paradox. Circulation 2006;114:838-854.

126. McMurray J, Solomon S, Pieper K, et al: The effect of valsar-tan, captopril, or both on atherosclerotic events after acute myocardial infarction: An analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J Am Coll Cardiol 2006;47:726-733.

127. Demers C, McMurray JJ, Swedberg K, et al: Impact of cande-sartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure. JAMA 2005;294: 1794-1798.

128. Tsuyuki RT, McDonald MA: Angiotensin receptor blockers do not increase risk of myocardial infarction. Circulation 2006;114:855-860.

129. Sleight P: The ONTARGET/TRANSCEND Trial Programme: Baseline data. Acta Diabetol 2005;42(Suppl 1):S50-S56.

130. Mochizuki S, Shimizu M, Taniguchi I, et al: JIKEI HEART Study—A morbi-mortality and remodeling study with valsar-tan in Japanese patients with hypertension and cardiovascular disease. Cardiovasc Drugs Ther 2004;18:305-309.

131. Abuissa H, Jones PG, Marso SP, O'Keefe JH Jr: Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: A meta-analysis of randomized clinical trials. J Am Coll Cardiol 2005;46: 821-826.

132. Aguilar D, Solomon SD: ACE inhibitors and angiotensin receptor antagonists and the incidence of new-onset diabetes mellitus: An emerging theme. Drugs 2006;66:1169-1177.

133. Bosch J, Yusuf S, Gerstein HC, et al: Effect of ramipril on the incidence of diabetes. N Engl J Med 2006;355:1551-1562.

134. Ingelfinger JR, Solomon CG: Angiotensin-converting-enzyme inhibitors for impaired glucose tolerance—Is there still hope? N Engl J Med 2006;355:1608-1610.

135. Haffner S, Hotman R, Califf R, et al: Targeting post-prandial hyperglycemia to prevent type 2 diabetes: Rationale and design of the NAVIGATOR trial [abstract]. Diabetologia 2002;45(Suppl 2):319.

136. Staessen JA, Li Y, Richart T: Oral renin inhibitors. Lancet 2006;368:1449-1456.

137. Azizi M, Webb R, Nussberger J, Hollenberg NK: Renin inhibition with aliskiren: Where are we now, and where are we going? J Hypertens 2006;24:243-256.

138. Cesari M, Rossi GP, Pessina AC: Biological properties of the angiotensin peptides other than angiotensin II: Implications for hypertension and cardiovascular diseases. J Hypertens 2002;20:793-799.

139. Anand K, Mooss AN, Hee TT, Mohiuddin SM: Meta-analysis: Inhibition of renin-angiotensin system prevents new-onset atrial fibrillation. Am Heart J 2006;152:217-222.

CHAPTER

Your Heart and Nutrition

Your Heart and Nutrition

Prevention is better than a cure. Learn how to cherish your heart by taking the necessary means to keep it pumping healthily and steadily through your life.

Get My Free Ebook


Post a comment